De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis
Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.BACKGROUNDPhase II and observational studies support the use of rituximab in multiple sclerosis. Standard...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis Jg. 27; H. 8; S. 1230 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
01.07.2021
|
| ISSN: | 1477-0970, 1477-0970 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.BACKGROUNDPhase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.To evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.OBJECTIVETo evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.Patients were switched from rituximab 1000 to 500 mg/6 months and prospectively followed for 12 months. Relapses, disability, occurrence of brain/spinal magnetic resonance imaging (MRI) lesions, serum neurofilament light chain (NfL), CD19+ B cell, and IgG concentrations were analyzed.METHODSPatients were switched from rituximab 1000 to 500 mg/6 months and prospectively followed for 12 months. Relapses, disability, occurrence of brain/spinal magnetic resonance imaging (MRI) lesions, serum neurofilament light chain (NfL), CD19+ B cell, and IgG concentrations were analyzed.Fifty-nine patients were included (37 relapsing-remitting, 22 secondary progressive). No relapses occurred, with no difference in expanded disability status scale (EDSS) between baseline (4 (2.5-4.5) and 12 months (3.5 (2.5-5.5) p = 0.284). Overall, three new T2 lesions appeared during follow-up. NfL concentration was stable between baseline (7.9 (5.9-45.2) pg/mL) and 12 months (9.1 (5.9-21.3) pg/mL, p = 0.120). IgG concentrations decreased with greater rituximab load (coefficient = -0.439, p = 0.041). IgG deficient patients had greater risk of infections (OR = 6.27, 95% CI = 1.71-22.9, p = 0.005).RESULTSFifty-nine patients were included (37 relapsing-remitting, 22 secondary progressive). No relapses occurred, with no difference in expanded disability status scale (EDSS) between baseline (4 (2.5-4.5) and 12 months (3.5 (2.5-5.5) p = 0.284). Overall, three new T2 lesions appeared during follow-up. NfL concentration was stable between baseline (7.9 (5.9-45.2) pg/mL) and 12 months (9.1 (5.9-21.3) pg/mL, p = 0.120). IgG concentrations decreased with greater rituximab load (coefficient = -0.439, p = 0.041). IgG deficient patients had greater risk of infections (OR = 6.27, 95% CI = 1.71-22.9, p = 0.005).De-escalating rituximab dose from 1000 to 500 mg/6 months is safe, results in clinical and radiological stability, and does not affect serum NfL over 12 months. Rituximab load negatively influences IgG concentrations, and IgG deficient patients are at higher risk of infections.CONCLUSIONDe-escalating rituximab dose from 1000 to 500 mg/6 months is safe, results in clinical and radiological stability, and does not affect serum NfL over 12 months. Rituximab load negatively influences IgG concentrations, and IgG deficient patients are at higher risk of infections. |
|---|---|
| AbstractList | Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.BACKGROUNDPhase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy between low- and high-dose regimens.To evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.OBJECTIVETo evaluate effectiveness and safety of de-escalating rituximab dose from 1000 to 500 mg/6 months in multiple sclerosis.Patients were switched from rituximab 1000 to 500 mg/6 months and prospectively followed for 12 months. Relapses, disability, occurrence of brain/spinal magnetic resonance imaging (MRI) lesions, serum neurofilament light chain (NfL), CD19+ B cell, and IgG concentrations were analyzed.METHODSPatients were switched from rituximab 1000 to 500 mg/6 months and prospectively followed for 12 months. Relapses, disability, occurrence of brain/spinal magnetic resonance imaging (MRI) lesions, serum neurofilament light chain (NfL), CD19+ B cell, and IgG concentrations were analyzed.Fifty-nine patients were included (37 relapsing-remitting, 22 secondary progressive). No relapses occurred, with no difference in expanded disability status scale (EDSS) between baseline (4 (2.5-4.5) and 12 months (3.5 (2.5-5.5) p = 0.284). Overall, three new T2 lesions appeared during follow-up. NfL concentration was stable between baseline (7.9 (5.9-45.2) pg/mL) and 12 months (9.1 (5.9-21.3) pg/mL, p = 0.120). IgG concentrations decreased with greater rituximab load (coefficient = -0.439, p = 0.041). IgG deficient patients had greater risk of infections (OR = 6.27, 95% CI = 1.71-22.9, p = 0.005).RESULTSFifty-nine patients were included (37 relapsing-remitting, 22 secondary progressive). No relapses occurred, with no difference in expanded disability status scale (EDSS) between baseline (4 (2.5-4.5) and 12 months (3.5 (2.5-5.5) p = 0.284). Overall, three new T2 lesions appeared during follow-up. NfL concentration was stable between baseline (7.9 (5.9-45.2) pg/mL) and 12 months (9.1 (5.9-21.3) pg/mL, p = 0.120). IgG concentrations decreased with greater rituximab load (coefficient = -0.439, p = 0.041). IgG deficient patients had greater risk of infections (OR = 6.27, 95% CI = 1.71-22.9, p = 0.005).De-escalating rituximab dose from 1000 to 500 mg/6 months is safe, results in clinical and radiological stability, and does not affect serum NfL over 12 months. Rituximab load negatively influences IgG concentrations, and IgG deficient patients are at higher risk of infections.CONCLUSIONDe-escalating rituximab dose from 1000 to 500 mg/6 months is safe, results in clinical and radiological stability, and does not affect serum NfL over 12 months. Rituximab load negatively influences IgG concentrations, and IgG deficient patients are at higher risk of infections. |
| Author | Fucili, Anita Pravatà, Emanuele Zecca, Chiara Ripellino, Paolo Scotti, Barbara Kuhle, Jens Sacco, Rosaria Gobbi, Claudio Disanto, Giulio Riccitelli, Gianna C |
| Author_xml | – sequence: 1 givenname: Giulio surname: Disanto fullname: Disanto, Giulio – sequence: 2 givenname: Paolo surname: Ripellino fullname: Ripellino, Paolo – sequence: 3 givenname: Gianna C surname: Riccitelli fullname: Riccitelli, Gianna C – sequence: 4 givenname: Rosaria surname: Sacco fullname: Sacco, Rosaria – sequence: 5 givenname: Barbara surname: Scotti fullname: Scotti, Barbara – sequence: 6 givenname: Anita surname: Fucili fullname: Fucili, Anita – sequence: 7 givenname: Emanuele surname: Pravatà fullname: Pravatà, Emanuele – sequence: 8 givenname: Jens surname: Kuhle fullname: Kuhle, Jens – sequence: 9 givenname: Claudio surname: Gobbi fullname: Gobbi, Claudio – sequence: 10 givenname: Chiara surname: Zecca fullname: Zecca, Chiara |
| BookMark | eNpNjDtPwzAUhS1UJNrCzuiRgYAfcZ2MqDylSiwwV7ZzXRk5dsl1EIz8cyLKwHB0HtL5FmSWcgJCzjm74lzray6VqFWjBGsnydURmfNa64q1ms3-5ROyQHxjjGkt1Zx830IF6Ew0JaQdHUIZP0NvLO0yAh0Ax1iQhkSxGBtiKF80e-piSGE6XdLBdCHHvDs0kzqKMIw9TTAO2YdoekiFRviA-IvpJ17YR6DoIgwZA56SY28iwtmfL8nr_d3L-rHaPD88rW82lZO1KFXjZdM4xY3lauUFm6wREoxpXGutAtsy5abdc5Deq67xhisrLKt9Z7TuxJJcHLj7Ib-PgGXbB3QQo0mQR9yKWmou2ppz8QO6YWjR |
| CitedBy_id | crossref_primary_10_1007_s40120_023_00535_z crossref_primary_10_3390_ijms241310787 crossref_primary_10_1016_j_msard_2021_103485 crossref_primary_10_1111_bcpt_13932 crossref_primary_10_1177_13524585211069068 crossref_primary_10_1016_j_msard_2023_104518 crossref_primary_10_1016_j_msard_2023_105009 crossref_primary_10_1177_1756286421999631 crossref_primary_10_3390_cells14080606 crossref_primary_10_1016_j_msard_2025_106552 crossref_primary_10_1016_j_neurot_2025_e00603 crossref_primary_10_1007_s00415_025_13093_1 crossref_primary_10_3389_fneur_2024_1380654 crossref_primary_10_1016_j_msard_2025_106668 crossref_primary_10_1177_13524585251335466 crossref_primary_10_1016_j_msard_2023_104729 crossref_primary_10_3389_fimmu_2021_661882 crossref_primary_10_1007_s11910_021_01119_w crossref_primary_10_1007_s10072_022_06582_y crossref_primary_10_1007_s15010_025_02479_y crossref_primary_10_1038_s41598_024_53838_y crossref_primary_10_1007_s00415_024_12584_x crossref_primary_10_1002_14651858_CD013874_pub3 crossref_primary_10_1007_s40265_024_02011_w crossref_primary_10_1007_s00415_025_13133_w crossref_primary_10_1136_bmjno_2024_000672 crossref_primary_10_1177_13524585211065711 crossref_primary_10_3389_fneur_2024_1500763 crossref_primary_10_1007_s00415_022_11197_6 |
| ContentType | Journal Article |
| DBID | 7X8 |
| DOI | 10.1177/1352458520952036 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-0970 |
| GroupedDBID | --- .2E .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31U 31X 31Z 36B 4.4 53G 54M 5VS 7X8 8R4 8R5 AABOD AACMV AACTG AAEWN AAGMC AAJPV AAKGS AAPEO AAPII AAQXI AARDL AATAA AATBZ AAUAS ABAFQ ABAWP ABCCA ABCJG ABHFT ABHQH ABIDT ABJIS ABJNI ABJZC ABLUO ABNCE ABPNF ABQKF ABQXT ABUJY ABVFX ACARO ACDXX ACFEJ ACGFO ACGFS ACGZU ACJTF ACLFY ACLZU ACOXC ACPRK ACROE ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADNON ADRRZ ADVBO ADZYD AECGH AEDTQ AEKYL AENEX AEPTA AERKM AESZF AEUHG AEWDL AEWHI AFKBI AFKRG AFMOU AFQAA AGHKR AGKLV AGPXR AGWFA AGWNL AHDMH AHMBA AJGYC AJHME AJUZI AJVBE AJXAJ ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV AUTPY AYAKG B3H B8R B8Z B94 BBRGL BDDNI BKIIM BPACV BSEHC BWJAD BYIEH CS3 DB0 DF0 DO- DU5 DV7 DV9 EBS EMOBN F5P FD6 FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HZ~ J8X K.F N9A O9- P.B P2P Q1R Q2X Q7L Q7U Q83 ROL S01 SASJQ SAUOL SCNPE SDB SFC SFK SFT SGO SGR SGV SGZ SHG SNB SPJ SPQ SPV STM |
| ID | FETCH-LOGICAL-c342t-8f388c51ab156f20b15823eaa8c9bb5eb905cf20f1e3ff5d8fa15b2b04fda77d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 34 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000563056400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-0970 |
| IngestDate | Sun Sep 28 11:14:43 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c342t-8f388c51ab156f20b15823eaa8c9bb5eb905cf20f1e3ff5d8fa15b2b04fda77d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 2437129411 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2437129411 |
| PublicationCentury | 2000 |
| PublicationDate | 20210701 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 07 year: 2021 text: 20210701 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Multiple sclerosis |
| PublicationYear | 2021 |
| SSID | ssj0007735 |
| Score | 2.4816194 |
| Snippet | Phase II and observational studies support the use of rituximab in multiple sclerosis. Standard protocols are lacking, but studies suggest comparable efficacy... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 1230 |
| Title | De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis |
| URI | https://www.proquest.com/docview/2437129411 |
| Volume | 27 |
| WOSCitedRecordID | wos000563056400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NS8QwEA3qinjxW_wmgsct2yTtJjmJqIsXFw8Ke1vSfEBht9VtK3r0nzuJLXvwIngqlFBCOp15yXudh9CVYEYDLmCA3LSOEmviSPlGkEyaoZHMUpaoYDbBx2Mxmcin9sCtamWVXU4MidqU2p-RD3zjPKhNCSHXr2-Rd43y7GprobGKegygjJd08cmyWzjnwWCTJJxHseTxkqYcEAAeCUBlChDDc3G_UnGoL6Pt_85sB221yBLf_ITCLlqxxR7aeGy58330dWcjW8ErUV7pjBd53Xzkc5VhU1YWw667mdUVzgsMeDEoZj9x6XD352QfL5TJu0zZx6owGKK3mePQEdPlEFlQv_DMi5DCYzqpIq5gOlCL8-oAvYzun28fotaAIdIsoXUkHBNCp0RlsMtzNIaLoMwqJbTMstRmMk413HfEMudSI5wiaUazOHFGcW7oIVorysIeIUydE0MJQ6mxSapZNpRKGM6VczKVQ3KMLrvFnUKAe9ZCFbZsqulyeU_-MOYUbVKvOgmC2jPUc_AR23O0rt_rvFpchPj4BgMZx50 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=De-escalating+rituximab+dose+results+in+stability+of+clinical%2C+radiological%2C+and+serum+neurofilament+levels+in+multiple+sclerosis&rft.jtitle=Multiple+sclerosis&rft.au=Disanto%2C+Giulio&rft.au=Ripellino%2C+Paolo&rft.au=Riccitelli%2C+Gianna+C&rft.au=Sacco%2C+Rosaria&rft.date=2021-07-01&rft.issn=1477-0970&rft.eissn=1477-0970&rft.volume=27&rft.issue=8&rft.spage=1230&rft_id=info:doi/10.1177%2F1352458520952036&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon |